Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0030193 (pain)
 261,466 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A placebo-controlled, double-blind study of triphasic oral contraceptives for prospectively confirmed premenstrual syndrome (PMS) was conducted with 82 subjects, 59 of whom completed the study and who were later confirmed to have moderate to severe premenstrual symptoms. 212 subjects were recruited between April 1987 - June 1988, and completed a menstrual history form and a 95-item retrospective questionnaire on premenstrual symptoms. Subjects took Synphasic (Syntex, Mississauga, Canada) containing 35 mcg ethinyl estradiol and 0.5 mg, 1.0 mg, and 0.5 mg norethindrone. Subjects were monitored for 1 menstrual cycle for baseline, then took triphasic or placebo for 3 cycles. 23 oral contraceptive taking and 36 placebo subjects completed the trial: completers had higher status occupations and lower symptom severity scores than dropouts. Both pill and placebo groups showed significant clinical improvement on every symptom except headache. Symptom scores decreased significantly between baseline and 3rd treatment cycle, and between menstrual phase scores and the variables "mood swings," "more sleep," "unhappy," and "tense" in the 2nd treatment cycle compared with the 1st treatment cycle in both groups. In the pill group ratings of premenstrual breast pain were significantly lower in the 3rd treatment cycle compared with baseline (p0.05), and to the 1st treatment cycle (p0.01). No significant changes in breast pain were found in the placebo group. Some pill cycles showed significant reduction in edema. Those in the pill group who were initially rated as "depressed" showed greater improvement in work impairment, sleep requirements, and energy level premenstrually. The pill group, however, reported significantly lower sexual interest during treatment. This is the 1st reported double-blind, placebo-controlled, prospectively confirmed study of oral contraceptives for PMS.
 ...
PMID:A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. 156 78

60,000 women in France have received RU 486 and a prostaglandin to induce abortion. In the late 1980's, clinical researchers assessed the safety and effectiveness of 600 mg of oral RU 486 in 2040 French women. 2 days later, health workers either injected 0.25-0.5mg of sulprostone or inserted a 1mg vaginal suppository of gemeprost in 1964 women who had not yet aborted. 96% experienced complete abortions. Physicians needed to conduct either a vacuum aspiration of dilation and curettage on the other 4%. RU 486 was most successful with 0.5mg of sulprostone, but these women also experienced considerable vaginal bleeding and pain. Overall uterine bleeding occurred for 8.9 days. The researchers recommended that adequate medical facilities be accessible to women using this method. Mild side effects were nausea, vomiting, and diarrhea. Efficacy and safety matched those of other early abortion methods. In April 1991, a grand multiparous women who smoked heavily and received RU 486 and a prostaglandin died--the 1st reported RU 486 related death. RU 486 may be able to treat fibroids, endometriosis, premenstrual syndrome, meningioma, hypertension, adrenal cancer, glaucoma, some forms of Cushing's syndrome, and breast cancer. The US Food and Drug Administration forbade the commercial import of RU 486 in 1989, even though it deemed RU 486 safe and effective. FDA considered the antiabortion view of the Bush Administration when making this decision. It made this decision despite the fact that abortion was still legal. RU 486 should be available soon for use as an abortifacient in the UK, the Netherlands, Sweden, Norway, Denmark, and Finland. These countries do not intent providing it to US women, however. Further the manufacturer is not willing to provide it to US researchers because it is afraid of antiabortion repercussions which may jeopardize WHO's approval of RU 486.
 ...
PMID:The RU 486 story: the French experience. 173 8

Research on the premenstrual syndrome (PMS) has been impeded by a lack of reliable and valid assessment techniques. The premenstrual assessment form (PAF), although a valid and reliable instrument, consists of 95 questions, requires extensive periods of time to complete and may be inappropriate for some clinical and research purposes. A study was designed to shorten the PAF and to test the validity and reliability of the shortened instrument. Twenty items that were most frequently reported to change during the week prior to menses were selected from the 95-item PAF form. The 20-item PAF form was administered at the baseline and 6- and 12-month follow-up clinic visits. A factor analysis identified three subscales: affect, water retention and pain. Our results showed that a shortened, 10-item version of the PAF had high internal consistency and reliability. A comparison of the symptoms on the 10-item PAF scale to reported nicotine withdrawal symptoms indicated that while the two correlated, the intercorrelation between the PAF subscales and the total PAF over time was higher. Thus, the 10-item PAF appears to measure a somewhat distinct and relatively stable set of symptoms. The 10-item PAF is a reliable and valid instrument that can be used to assess PMS when the study design or clinical need precludes the use of a 95-item PAF.
 ...
PMID:The shortened premenstrual assessment form. 176 53

The prevalence of premenstrual syndrome (PMS) was determined in 1600 women belonging to various socioeconomic groups in Karachi. Of the total, 33% had PMS, whose prevalence was high in lower socioeconomic group living in socially deprived areas. A direct association of PMS was noted with parity, being low in low parity group. Major complaints were pain in lower abdomen, cramps and backache with majority taking no treatment for their complaints.
 ...
PMID:Prevalence of premenstrual syndrome in Pakistani women. 186 51

Many conditions in clinical neurology may be responsive to pyridoxine as a therapeutic agent. The current difficulty is in trying to isolate the conditions that are most likely to respond. Treating seizures is a major part of a neurologic practice. Our current therapeutic agents are only partially successful and limited by multiple side effects. One problem is that patients often have to take these agents for an entire lifetime, further raising the risk of toxicity. If pyridoxine supplementation can improve the efficacy of currently used medications, it will be gladly accepted into our therapeutic arsenal. Headache, chronic pain, and depression all appear to run together in many of our patients. The observations that serotonin deficiency is a common thread between them and that pyridoxine can raise serotonin levels open a wide range of therapeutic options. Small studies have been carried out with mixed success. Comparison with amitriptyline in the treatment of headache appears to show about equal efficacy, although side effects would be expected to be more of a problem with the amitriptyline. Behavioral disorders are relatively common and continue to be a major problem, disrupting the lives of the patients and their families. Current treatments are not acceptable to most people because of the risk of side effects with long-term usage. If, as Dr. Feingold suggests, many of these problems are caused by "toxic" exposures to chemicals that are pyridoxine antagonists, supplementation at early ages may reduce the incidence of hyperactivity and aggressive behavior. This raises the question of safety. Is pyridoxine safe for long-term use in large segments of the population, including children? The studies on children with Down's syndrome and autism, utilizing much higher doses than are used for other therapeutic purposes, seem to indicate relative safety if carefully monitored. Studies involving large population groups with carpal tunnel syndrome, all adults, using 100-150 mg/day have shown minimal or no toxicity in five- to 10-year studies. Women self-medicating for PMS taking 500 to 5000 mg/day have shown peripheral neuropathy within one to three years. It would appear from this retrospective analysis that pyridoxine is safe at doses of 100 mg/day or less in adults. In children there is not enough data to make any sort of suggestion. Because the major neurologic complication is a peripheral neuropathy and the causes of this condition are myriad, pyridoxine may cause neuropathy only in patients with a pre-existing susceptibility to this condition.
 ...
PMID:Vitamin B6 in clinical neurology. 216 44

Cyclic pelvic pain is a common gynecologic problem caused by relatively few diseases, which usually can be diagnosed and remedied quickly. Some complaints reflect normal physiologic aspects of the menstrual cycle (mittelschmerz, menstrual awareness). Premenstrual syndrome can be diagnosed, but an effective and convenient treatment is lacking. Dysmenorrhea is the commonest source of cyclic pain, diagnosed by its characteristic history and rapid relief on administration of antiprostaglandin agents. Endometriosis is diagnosed surgically and best treated either surgically then, or medically by danazol or GnRH agonists. In contrast, adenomyosis is a problem commonly encountered in later life, and hysterectomy is usually needed for both definitive diagnosis and treatment.
 ...
PMID:Cyclic pelvic pain. 223 52

The factor structure of the Dutch adaptation of the Menstrual Distress Questionnaire (MDQ) was studied in a group of 702 women with high probability of premenstrual symptoms. The original factor pattern could not be replicated. Essentially four factors were found: negative affect, concentration, pain, and water retention. This indicates the importance of psychological and somatic symptoms in the premenstrual syndrome.
 ...
PMID:The factor structure of the Menstrual Distress Questionnaire--Dutch. 237 87

The prostaglandin system is thought to play a role in the etiology of the premenstrual syndrome. Many authors describe that prostaglandins are involved in both central and peripheral symptoms. To test this hypothesis, we studied the effects of naproxen sodium treatment (550 mg twice daily, from day -7, in relation to next menses, to the 4th day of the cycle) in 34 patients suffering from premenstrual syndrome. Six cases dropped out. Fourteen women were given placebo for the first three cycles of the trial, followed by active drug. The other 14 patients were given naproxen sodium, beginning from the first cycle. In order to evaluate premenstrual symptoms, the Moos menstrual distress questionnaire was prospectively applied during the 2-month run-in period and at the 3rd and 6th cycles of treatment. During our double-blind naproxen sodium study, both menstrual and premenstrual 'pain' decreased during active drug treatment, while placebo was ineffective. We also obtained a significant improvement of premenstrual 'behavioral changes' which is probably related to the relief of painful symptomatology. In conclusion, this study indicates that naproxen sodium is a useful and safe drug in the treatment of premenstrual and menstrual pain related symptoms.
 ...
PMID:Naproxen sodium in the treatment of premenstrual symptoms. A placebo-controlled study. 269 13

Plasma beta-endorphin (beta-EP), beta-lipotropin (beta-LPH), and cortisol concentrations were measured by perimenstrual period in 11 patients affected by premenstrual syndrome (PMS) and in 8 asymptomatic healthy volunteers. Blood samples were collected every 2 to 3 days, for 1 month, starting from midcycle. The Menstrual Distress Questionnaire (MDQ) was administered during the testing period. Plasma beta-LPH and cortisol levels remain stable during the perimenstrual period, in both controls and PMS patients. On the contrary, PMS patients showed a decrease of plasma beta-EP in the week preceding menses and during the first days of menstrual flow. Beta-EP values of PMS patients regain normal levels during the next follicular phase. No changes of beta-EP levels were recorded in asymptomatic women. MDQ scores revealed that PMS patients complained of water retention, pain discomfort, and mood swings. The transient and reversible decrease of plasma beta-EP in PMS patients near to and at menses remains to be clarified.
 ...
PMID:Premenstrual fall of plasma beta-endorphin in patients with premenstrual syndrome. 295 25

The effects of experimentally induced and personally relevant stressors on low back EMG activity during 3 phases of the menstrual cycle in women with the premenstrual syndrome (PMS) and premenstrual low back pain were examined. Thirty-nine women reporting either PMS and premenstrual severe low back pain (group 1), PMS with premenstrual moderate low back pain (group 2), or those reporting neither condition (group 3) participated. During each of 3 menstrual phase-specific assessment sessions, participants were exposed to a neutral stimulus, an experimentally induced stressor, and 2 personally relevant stressors in a randomized order. Concomitant monitoring of low back EMG activity and heart interbeat interval was undertaken. Results indicated that participants in group 1 evidenced greater EMG changes in response to personal stressors compared to the neutral stimulus and experimentally induced stress during the premenstrual phase. EMG activity in response to personal stress was also significantly higher during the premenstrual phase than during the menstrual and intermenstrual phases for group 1, and higher than EMG changes evidenced by groups 2 and 3 during the same phase. Group 2, while not reporting as severe premenstrual back pain as did group 1, reported moderate levels of back pain and evidenced greater physiological reactivity to a personal stressor than did group 3. The findings highlight the link between personally relevant stressors and concomitant physiologic responsivity and the role that this arousal may play in the maintenance and exacerbation of premenstrual low back pain.
Pain 1988 Aug
PMID:The premenstrual syndrome: psychophysiologic concomitants of perceived stress and low back pain. 297 13


1 2 3 4 5 6 7 8 9 Next >>